BMO Hosts Second Annual Obesity Summit on the Future of the GLP-1+ Market
BMO is set to host its second annual Obesity Summit on March 25, 2025, in New York, focusing on the expanding $150 billion obesity therapies market. The summit will bring together healthcare industry experts and leaders to examine trends in metabolic disease and drug therapies.
The event features prominent companies including Altimmune, Amgen, Corbus Pharmaceuticals, Eli Lilly, FlyteHealth, Novo Nordisk, Roman Health, Scholar Rock, and Structure Therapeutics. Participants will explore advances in GLP-1 drug therapies with insights from pharmacy benefit managers, patients, and providers.
The summit's agenda includes fireside chats, expert panels, and presentations featuring BMO Sr. Biotechnology & Pharmaceuticals Analyst Evan Seigerman, FlyteHealth Co-Founder Dr. Katherine Saunders, and Dr. Louis J. Aronne, Sanford I. Weill Professor of Metabolic Research. Key topics include care delivery, emerging technologies, coverage and access, and patient insights on GLP-1+ therapy.
BMO ospiterà il suo secondo Obesity Summit annuale il 25 marzo 2025 a New York, concentrandosi sull'espansione del mercato delle terapie per l'obesità da 150 miliardi di dollari. Il summit riunirà esperti e leader del settore sanitario per esaminare le tendenze nelle malattie metaboliche e nelle terapie farmacologiche.
L'evento vedrà la partecipazione di aziende di spicco come Altimmune, Amgen, Corbus Pharmaceuticals, Eli Lilly, FlyteHealth, Novo Nordisk, Roman Health, Scholar Rock e Structure Therapeutics. I partecipanti esploreranno i progressi nelle terapie farmacologiche GLP-1 con approfondimenti forniti da gestori di benefici farmaceutici, pazienti e fornitori.
Il programma del summit include conversazioni informali, panel di esperti e presentazioni con la partecipazione dell'analista senior di biotecnologie e farmaceutici di BMO, Evan Seigerman, della co-fondatrice di FlyteHealth, Dr. Katherine Saunders, e del Dr. Louis J. Aronne, Professore di Ricerca Metabolica presso Sanford I. Weill. I temi principali includono la fornitura di assistenza, le tecnologie emergenti, la copertura e l'accesso, e le opinioni dei pazienti sulla terapia GLP-1+.
BMO llevará a cabo su segundo Obesity Summit anual el 25 de marzo de 2025 en Nueva York, centrándose en el creciente mercado de terapias para la obesidad de 150 mil millones de dólares. La cumbre reunirá a expertos y líderes de la industria de la salud para examinar las tendencias en enfermedades metabólicas y terapias farmacológicas.
El evento contará con la participación de empresas destacadas como Altimmune, Amgen, Corbus Pharmaceuticals, Eli Lilly, FlyteHealth, Novo Nordisk, Roman Health, Scholar Rock y Structure Therapeutics. Los participantes explorarán los avances en terapias farmacológicas GLP-1 con información de gerentes de beneficios farmacéuticos, pacientes y proveedores.
La agenda de la cumbre incluye charlas informales, paneles de expertos y presentaciones con la participación del analista senior de biotecnología y farmacéuticos de BMO, Evan Seigerman, la cofundadora de FlyteHealth, Dra. Katherine Saunders, y el Dr. Louis J. Aronne, Profesor de Investigación Metabólica en Sanford I. Weill. Los temas clave incluyen la entrega de atención, tecnologías emergentes, cobertura y acceso, y las opiniones de los pacientes sobre la terapia GLP-1+.
BMO는 2025년 3월 25일 뉴욕에서 두 번째 연례 비만 정상 회담을 개최하여 1,500억 달러 규모의 비만 치료 시장의 확장에 초점을 맞출 예정입니다. 이번 정상 회담에서는 대사 질환 및 약물 치료의 동향을 살펴보기 위해 의료 산업 전문가와 리더들이 모입니다.
이 행사에는 Altimmune, Amgen, Corbus Pharmaceuticals, Eli Lilly, FlyteHealth, Novo Nordisk, Roman Health, Scholar Rock, Structure Therapeutics와 같은 저명한 기업들이 참여합니다. 참가자들은 약국 혜택 관리자, 환자 및 제공자의 통찰력을 바탕으로 GLP-1 약물 치료의 발전을 탐구할 것입니다.
정상 회담의 agenda에는 BMO의 선임 생명공학 및 제약 분석가인 Evan Seigerman, FlyteHealth의 공동 창립자인 Dr. Katherine Saunders, Sanford I. Weill의 대사 연구 교수인 Dr. Louis J. Aronne이 포함된 전문가 패널과 프레젠테이션이 포함됩니다. 주요 주제에는 치료 제공, 신기술, 보장 및 접근성, 그리고 GLP-1+ 치료에 대한 환자의 통찰력이 포함됩니다.
BMO organisera son deuxième Obesity Summit annuel le 25 mars 2025 à New York, en mettant l'accent sur l'expansion du marché des thérapies contre l'obésité de 150 milliards de dollars. Le sommet rassemblera des experts et des leaders de l'industrie de la santé pour examiner les tendances des maladies métaboliques et des thérapies médicamenteuses.
L'événement mettra en vedette des entreprises de premier plan telles que Altimmune, Amgen, Corbus Pharmaceuticals, Eli Lilly, FlyteHealth, Novo Nordisk, Roman Health, Scholar Rock et Structure Therapeutics. Les participants exploreront les avancées des thérapies médicamenteuses GLP-1 avec des perspectives fournies par des gestionnaires de prestations pharmaceutiques, des patients et des fournisseurs.
L'agenda du sommet comprend des discussions informelles, des panels d'experts et des présentations avec la participation de l'analyste senior en biotechnologie et pharmacie de BMO, Evan Seigerman, de la co-fondatrice de FlyteHealth, Dr. Katherine Saunders, et du Dr. Louis J. Aronne, Professeur de recherche métabolique à Sanford I. Weill. Les sujets clés incluent la prestation de soins, les technologies émergentes, la couverture et l'accès, ainsi que les avis des patients sur la thérapie GLP-1+.
BMO wird am 25. März 2025 in New York seinen zweiten jährlichen Obesity Summit ausrichten, der sich auf den wachsenden Markt für Adipositas-Therapien im Wert von 150 Milliarden Dollar konzentriert. Der Gipfel bringt Experten und Führungskräfte der Gesundheitsbranche zusammen, um Trends in Bezug auf Stoffwechselerkrankungen und Arzneimitteltherapien zu untersuchen.
Die Veranstaltung umfasst prominente Unternehmen wie Altimmune, Amgen, Corbus Pharmaceuticals, Eli Lilly, FlyteHealth, Novo Nordisk, Roman Health, Scholar Rock und Structure Therapeutics. Die Teilnehmer werden Fortschritte bei GLP-1-Arzneimitteltherapien mit Einblicken von Arzneimittelverwaltungsmanagern, Patienten und Anbietern erkunden.
Die Agenda des Gipfels umfasst informelle Gespräche, Expertenpanels und Präsentationen mit BMO-Senioranalysten für Biotechnologie und Pharma, Evan Seigerman, der Mitbegründerin von FlyteHealth, Dr. Katherine Saunders, und Dr. Louis J. Aronne, Professor für Stoffwechselforschung an der Sanford I. Weill. Zu den wichtigsten Themen gehören die Bereitstellung von Pflege, aufkommende Technologien, Deckung und Zugang sowie Patientenmeinungen zur GLP-1+-Therapie.
- BMO positioning itself as a thought leader in the rapidly growing $150 billion obesity therapies market
- High-profile participation from major pharmaceutical companies indicates strong industry engagement
- None.
Healthcare industry experts and leaders to convene March 25 at the 2025 BMO Obesity Summit to examine outlook and trends in metabolic disease and drug therapies
What: | 2025 BMO Obesity Summit |
When: | Tuesday, March 25, 2025 |
Where: | Convene, 360 Madison Ave, |
Media: | Register here |
The BMO Obesity Summit will deliver thought leadership and corporate management perspectives in a variety of formats such as fireside chats, expert panels and presentations, including:
- Discussions with leading life sciences companies hosted by BMO analysts, including Sr. Biotechnology & Pharmaceuticals Analyst, Evan Seigerman
- Obesity 102 with Katherine Saunders, MD, Obesity Physician & Co-Founder, FlyteHealth
- A discussion with Dr. Louis J. Aronne, M.D., Sanford I. Weill Professor of Metabolic Research
- Panels on care delivery, emerging technologies, coverage and access
- Insights from patients on GLP-1+ therapy
For more information or to request an interview with one of BMO's equity research analysts, please contact BMO Media Relations using the contact details below. Note: There may be restrictions for media on access to some presentations.
About BMO Financial Group
BMO Financial Group is the eighth largest bank in North America by assets, with total assets of
SOURCE BMO Financial Group
FAQ
When and where is BMO's 2025 Obesity Summit taking place?
What is the current size of the obesity therapies market discussed at the BMO Summit?
Which major pharmaceutical companies are participating in BMO's 2025 Obesity Summit?
What are the main topics being discussed at the 2025 BMO Obesity Summit?
